Our history

Our business idea is to help people with chronic conditions and illnesses by using a patented treatment method that is neither surgical nor drug-based. The treatment is called Kinetic Oscillation Stimulation and is abbreviated K.O.S.

Today, we focus on chronic nasal congestion (rhinitis) which affects about 1.3 percent of the world's population, and partly on chronic migraines that affect 1.4-2.2 percent of the population with severe and frequent headaches.

International establishment

K.O.S is a product system for neurostimulation therapy with long-term effects, which modulates the autonomic nervous system functions. The rhinitis treatment is CE-certified and is sold in the EU. The migraine treatment is in a clinical trial phase with the aim of being CE marked.

We want to establish our technology in the international market for neuromodulation. We sell our product system and our treatments through distributors to clinics and hospitals, who in turn treat the patients.

Listed on NGM-SME

Today, the company has three employees, supported by a handful of expert consultants with extensive overall experience in medical technology product development, international market establishment, and clinical study activities. The business is entirely focused on sales in a few selected markets and the implementation of the two ongoing studies.

Chordate Medical AB, the Group's operating company, is a wholly owned subsidiary of Chordate Medical Holding AB (Publ), which was listed on Nordic Growth Market-SME with the first trading day on March 8, 2017.

The company is based in Kista, outside Stockholm.